Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib Plus Tislelizumab in Advanced Biliary Tract Cancer
NCT04727996Phase 2Active, not recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Nov 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sitravatinib in biliary tract cancer (BTC), sponsored by Seoul National University Hospital. Primary endpoint: Disease Control Rate. Started Nov 2020; status: active, not recruiting.
02
Drugs
sitravatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04727996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727996.